These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20709666)

  • 1. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
    Parikh SA; Kantarjian H; Schimmer A; Walsh W; Asatiani E; El-Shami K; Winton E; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):285-9. PubMed ID: 20709666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
    O'Brien SM; Claxton DF; Crump M; Faderl S; Kipps T; Keating MJ; Viallet J; Cheson BD
    Blood; 2009 Jan; 113(2):299-305. PubMed ID: 18931344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
    Hwang JJ; Kuruvilla J; Mendelson D; Pishvaian MJ; Deeken JF; Siu LL; Berger MS; Viallet J; Marshall JL
    Clin Cancer Res; 2010 Aug; 16(15):4038-45. PubMed ID: 20538761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.
    Arellano ML; Borthakur G; Berger M; Luer J; Raza A
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):534-9. PubMed ID: 25052051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
    Paik PK; Rudin CM; Pietanza MC; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Lung Cancer; 2011 Dec; 74(3):481-5. PubMed ID: 21620511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
    Schimmer AD; O'Brien S; Kantarjian H; Brandwein J; Cheson BD; Minden MD; Yee K; Ravandi F; Giles F; Schuh A; Gupta V; Andreeff M; Koller C; Chang H; Kamel-Reid S; Berger M; Viallet J; Borthakur G
    Clin Cancer Res; 2008 Dec; 14(24):8295-301. PubMed ID: 19088047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
    Oki Y; Copeland A; Hagemeister F; Fayad LE; Fanale M; Romaguera J; Younes A
    Blood; 2012 Mar; 119(9):2171-2. PubMed ID: 22383790
    [No Abstract]   [Full Text] [Related]  

  • 9. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
    Chiappori A; Williams C; Northfelt DW; Adams JW; Malik S; Edelman MJ; Rosen P; Van Echo DA; Berger MS; Haura EB
    J Thorac Oncol; 2014 Jan; 9(1):121-5. PubMed ID: 24346101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
    Goy A; Hernandez-Ilzaliturri FJ; Kahl B; Ford P; Protomastro E; Berger M
    Leuk Lymphoma; 2014 Dec; 55(12):2761-8. PubMed ID: 24679008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
    Chiappori AA; Schreeder MT; Moezi MM; Stephenson JJ; Blakely J; Salgia R; Chu QS; Ross HJ; Subramaniam DS; Schnyder J; Berger MS
    Br J Cancer; 2012 Feb; 106(5):839-45. PubMed ID: 22333598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
    Schimmer AD; Raza A; Carter TH; Claxton D; Erba H; DeAngelo DJ; Tallman MS; Goard C; Borthakur G
    PLoS One; 2014; 9(10):e108694. PubMed ID: 25285531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
    Apostolidou E; Kantarjian H; Thomas D; Burger I; Borthakur G; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):281-4. PubMed ID: 20709665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
    Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
    Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
    PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
    Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
    Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
    Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
    Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
    Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
    Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.